<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Shattuck Labs Inc — News on 6ix</title>
<link>https://6ix.com/company/shattuck-labs-inc</link>
<description>Latest news and press releases for Shattuck Labs Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 05 Mar 2026 05:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/shattuck-labs-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c5e278dffbe2df11acc6.webp</url>
<title>Shattuck Labs Inc</title>
<link>https://6ix.com/company/shattuck-labs-inc</link>
</image>
<item>
<title>Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights-5</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights-5</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Phase 1 clinical trial of SL-325 ongoing, with data expected in the second quarter of 2026 –Phase 2 clinical trial of SL-325 in patients with Crohn’s disease</description>
</item>
<item>
<title>Shattuck Labs Announces Participation in Upcoming March Investor Conferences</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-participation-in-upcoming-march-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-participation-in-upcoming-march-investor-conferences</guid>
<pubDate>Wed, 25 Feb 2026 13:00:00 GMT</pubDate>
<description>AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences: Conference Details TD Cowen 46th Annual Health C</description>
</item>
<item>
<title>Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-participation-upcoming-133000200</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-participation-upcoming-133000200</guid>
<pubDate>Fri, 06 Feb 2026 13:30:00 GMT</pubDate>
<description>AUSTIN, TX and DURHAM, NC, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will participate in a fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium, taking place February</description>
</item>
<item>
<title>Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-inc-announces-inducement-211500247</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-inc-announces-inducement-211500247</guid>
<pubDate>Mon, 15 Dec 2025 21:15:00 GMT</pubDate>
<description>AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has granted inducement equity awards on December 10, 2025 (the “Grant Date”) to a newly-hired non-executive officer. The in</description>
</item>
<item>
<title>Shattuck Labs to Participate in Upcoming December Investor Conferences</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-participate-upcoming-december-130000383</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-participate-upcoming-december-130000383</guid>
<pubDate>Thu, 20 Nov 2025 13:00:00 GMT</pubDate>
<description>AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that Company management will participate in multiple investor conferences in December 2025. Conference Details Conference: Piper Sa</description>
</item>
<item>
<title>Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-reports-third-quarter-213000725</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-reports-third-quarter-213000725</guid>
<pubDate>Thu, 06 Nov 2025 21:30:00 GMT</pubDate>
<description>–First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers – – Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 – – Appointments of Dan Baker, M.D., and Mona Ashiya, Ph.D. to the Board of Directors – AUSTIN, TX and DURHAM, NC, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor</description>
</item>
<item>
<title>Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-participation-upcoming-115100834</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-participation-upcoming-115100834</guid>
<pubDate>Thu, 02 Oct 2025 11:51:00 GMT</pubDate>
<description>AUSTIN, TX and DURHAM, NC, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that Company management will participate in a panel discussion focused on key takeaways from the United European Gastroenterology Week (UEGW) Conference 2025. The ses</description>
</item>
<item>
<title>Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-closing-103-103000213</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-closing-103-103000213</guid>
<pubDate>Tue, 26 Aug 2025 10:30:00 GMT</pubDate>
<description>— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma cash and cash equivalents, assuming full exercise of common stock warrants, expected to fund planned operations into 2029 — — Industry expert Dan Baker, M.D., and OrbiMed representative Mona Ashiya, Ph.D., appointed to the Board of Directors — AUSTIN, TX and DURHAM, NC, Aug. 26, 202</description>
</item>
<item>
<title>Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-ind-sl-141700145</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-ind-sl-141700145</guid>
<pubDate>Thu, 21 Aug 2025 14:17:00 GMT</pubDate>
<description>– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases – – The Company is on track to dose the first participant in its Phase 1 SL-325 clinical trial in healthy volunteers in Q3 2025 – – Current cash and cash equivalents, plus the anticipated aggregate proceeds of up to $103 million from recent private placement, assuming full exercise of common stock warrants, expe</description>
</item>
<item>
<title>Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-reports-second-quarter-103000355</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-reports-second-quarter-103000355</guid>
<pubDate>Thu, 14 Aug 2025 10:30:00 GMT</pubDate>
<description>– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 – – On track to dose first participant in Phase 1 clinical trial for SL-325 in Q3 2025 – – Cash balance of approximately $50.5 million at end of Q2 2025 – – Aggregate proceeds from recent oversubscribed private placement of up to $103 million, less offering expenses, expected to fund operations into 2029 – AUSTIN, TX and DURHAM, NC, Aug. 14, 2</description>
</item>
<item>
<title>Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-oversubscribed-private-103000375</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-oversubscribed-private-103000375</guid>
<pubDate>Tue, 05 Aug 2025 10:30:00 GMT</pubDate>
<description>– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease – – Pro forma cash and cash equivalents from aggregate proceeds anticipated to fund operations into 2029 – AUSTIN, TX and DURHAM, NC, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor n</description>
</item>
<item>
<title>Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-participation-upcoming-110000039</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-participation-upcoming-110000039</guid>
<pubDate>Wed, 02 Jul 2025 11:00:00 GMT</pubDate>
<description>AUSTIN, TX and DURHAM, NC, July 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will participate in a DR3/TL1A focused panel discussion and participate in one-on-one meetings at the Leerink Partners Therapeutics Forum: I&I</description>
</item>
<item>
<title>Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-reports-first-quarter-202000143</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-reports-first-quarter-202000143</guid>
<pubDate>Thu, 01 May 2025 20:20:00 GMT</pubDate>
<description>– Company advances SL-325 program with an IND filing expected in the third quarter of 2025 – – Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, May 01, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-</description>
</item>
<item>
<title>Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-participation-upcoming-210000962</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-participation-upcoming-210000962</guid>
<pubDate>Wed, 02 Apr 2025 21:00:00 GMT</pubDate>
<description>AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present at and participate in one-on-one meetings at the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 202</description>
</item>
<item>
<title>Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-reports-fourth-quarter-110000089</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-reports-fourth-quarter-110000089</guid>
<pubDate>Thu, 27 Mar 2025 11:00:00 GMT</pubDate>
<description>– Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn’s and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class blocking antibody to DR3, the receptor for TL1A; data demonstrated favorable safety profile, full receptor occupancy, lack of DR3 agonism – – SL-325 advances toward Phase 1; on track for IND filing in the third quarter of 2025 – – Cash balance of approximately $73.0 million as of December 31, 202</description>
</item>
<item>
<title>Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-positive-data-140000449</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-positive-data-140000449</guid>
<pubDate>Thu, 20 Feb 2025 14:00:00 GMT</pubDate>
<description>– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate toxicology study – – SL-325 receptor occupancy (RO) and pharmacokinetic (PK) profile observed suggestive of extended dosing intervals; IND filing expected in the third quarter of 2025 – AUSTIN, TX & DURHAM, NC, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnolo</description>
</item>
<item>
<title>Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-oral-presentation-at-upcoming-20th-congress-of-european-crohns-and-colitis-organization-ecco-in-inflammatory-bowel-diseases-2025</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-oral-presentation-at-upcoming-20th-congress-of-european-crohns-and-colitis-organization-ecco-in-inflammatory-bowel-diseases-2025</guid>
<pubDate>Thu, 13 Feb 2025 05:00:00 GMT</pubDate>
<description>AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development</description>
</item>
<item>
<title>Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-poster-presentation-at-upcoming-2025-crohns-and-colitis-congress</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-poster-presentation-at-upcoming-2025-crohns-and-colitis-congress</guid>
<pubDate>Tue, 04 Feb 2025 05:00:00 GMT</pubDate>
<description>AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development</description>
</item>
<item>
<title>Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-presentation-at-the-43rd-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-announces-presentation-at-the-43rd-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Mon, 06 Jan 2025 05:00:00 GMT</pubDate>
<description>AUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development</description>
</item>
<item>
<title>Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025</title>
<link>https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-provides-corporate-update-and-highlights-upcoming-key-milestones-in-2025</link>
<guid isPermaLink="true">https://6ix.com/company/shattuck-labs-inc/news/shattuck-labs-provides-corporate-update-and-highlights-upcoming-key-milestones-in-2025</guid>
<pubDate>Thu, 02 Jan 2025 05:00:00 GMT</pubDate>
<description>AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development</description>
</item>
</channel>
</rss>